Dr. Reddy's Laboratories マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Erez Israeli

最高経営責任者

₹230.3m

報酬総額

CEO給与比率	n/a
CEO在任期間	8.2yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	4.4yrs

経営陣の近況

Recent updates

CEO報酬分析

Dr. Reddy's Laboratories の収益と比較して、Erez Israeli の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2026	₹230m	n/a	₹43b
Dec 31 2025	n/a	n/a	₹57b
Sep 30 2025	n/a	n/a	₹59b
Jun 30 2025	n/a	n/a	₹57b
Mar 31 2025	₹175m	n/a	₹57b
Dec 31 2024	n/a	n/a	₹54b
Sep 30 2024	n/a	n/a	₹53b
Jun 30 2024	n/a	n/a	₹56b
Mar 31 2024	₹197m	n/a	₹56b
Dec 31 2023	n/a	n/a	₹52b
Sep 30 2023	n/a	n/a	₹51b
Jun 30 2023	n/a	n/a	₹47b
Mar 31 2023	₹195m	n/a	₹45b
Dec 31 2022	n/a	n/a	₹36b
Sep 30 2022	n/a	n/a	₹31b
Jun 30 2022	n/a	n/a	₹30b
Mar 31 2022	₹127m	n/a	₹24b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹19b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹120m	n/a	₹17b
Dec 31 2020	n/a	n/a	₹21b
Sep 30 2020	n/a	n/a	₹15b
Jun 30 2020	n/a	n/a	₹19b
Mar 31 2020	₹195m	₹107m	₹19b

報酬と市場: Erezの総報酬 ($USD 2.44M ) は、 German市場 ($USD 5.47M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Erezの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。

CEO

Erez Israeli (58 yo)

8.2yrs

在職期間

₹230,330,000

報酬

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Gunupati Prasad	Co-Chairman	40.2yrs	₹158.17m	13.08% € 1.4b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.4yrs	₹100.66m	13.62% € 1.4b
Erez Israeli	CEO & Member of the Management Council	8.2yrs	₹230.33m	データなし
Mannam Venkatanarasimham	CFO & Member of the Management Council	1.8yrs	₹72.48m	0.0074% € 770.7k
Krishna Venkatesh	Global Head of IPDO	2.4yrs	₹41.18m	データなし
Deepak Sapra	Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council	no data	₹50.89m	0.0091% € 950.9k
Motupalli Ramana	CEO of Global Generics & Member of Management Council	no data	₹89.25m	0.0082% € 857.7k
Sanjay Sharma	Executive VP	8.8yrs	₹71.07m	データなし
Patrick Aghanian	Head of Consumer Health Organization & Member of Management Council	no data	₹107.54m	0.0010% € 105.8k
Bhethanabottla Phanimitra	Chief Digital & Information Officer and Member of the Management Council	2.8yrs	₹37.54m	0.0010% € 110.0k
Milan Kalawadia	CEO of North America & Member of Management Council	2.1yrs	₹86.78m	0.0057% € 594.8k
M S Sundar	Global Head of Quality and PV & Member of Management Council	less than a year	データなし	0.0043% € 448.2k

2.4yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: RDDAの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Gunupati Prasad	Co-Chairman	40.2yrs	₹158.17m	13.08% € 1.4b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.4yrs	₹100.66m	13.62% € 1.4b
Claudio Albrecht	Independent Director	3.1yrs	₹20.24m	データなし
Arun Kumar	Independent Director	3.8yrs	₹22.14m	データなし
Shikha Sharma	Independent Director	7.4yrs	₹16.45m	データなし
Leo Puri	Lead Independent Director	7.7yrs	₹22.62m	データなし
Kodumudi Krishnan	Independent Director	4.4yrs	₹14.18m	データなし
Sanjiv Mehta	Independent Director	2.5yrs	₹17.40m	データなし
Alpna Seth	Independent Director	3.4yrs	₹19.77m	データなし
Penny Wan	Independent Director	4.4yrs	₹20.72m	データなし

4.4yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: RDDAの取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/06/30 06:43
終値	2026/06/30 00:00
収益	2026/03/31
年間収益	2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページでご覧いただけます。また、レポートの使い方に関するガイドや YouTube のチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Dr. Reddy's Laboratories Limited 37 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。69

アナリスト	機関
Rohit Bhat	360 ONE Capital Market Private Limited
Gaurav Tinani	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited

Dr. Reddy's Laboratories マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Recent updates

Dr. Reddy's Laboratories Limited to Report Q1, 2027 Results on Jul 22, 2026

Dr. Reddy’s Laboratories Announces First-To-Market Launch Of Bosutinib Tablets 400Mg, A Generic Equivalent Of Bosulif, In The United States

Dr. Reddy’S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada

Dr. Reddy's Laboratories Limited announces Annual dividend, payable on August 22, 2026

Dr Reddys Laboratories Ltd Receives Health Canada Approval For Generic Semaglutide Injection

Enspirit Technology Services Private Limited entered into an agreement to acquire Svaas Wellness Limited from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 22.3 million.

CORONA Remedies Limited (NSEI:CORONA) acquired Wokadine Brand from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Limited to Report Q4, 2026 Results on May 12, 2026

Dr. Reddy's Announces USFDA Acceptance to Review its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%

Dr. Reddy's Laboratories Limited to Report Q3, 2026 Results on Jan 21, 2026

USFDA Inspection Closes with Voluntary Action Indicated Classification

Eisai Co., Ltd. Announces Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for AVT03 (denosumab), A Proposed Biosimilar of Prolia®? and Xgeva®?

Dr. Reddy's Laboratories Limited to Report Q2, 2026 Results on Oct 24, 2025

Extrovis AG and Dr. Reddy's Announce the Launch of the Authorized Generic of Carac (Fluorouracil Cream), 0.5% in the U.S

Dr. Reddy's Laboratories Limited to Report Q1, 2026 Results on Jul 23, 2025

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's Laboratories Limited Recommends A Final Dividend for the Financial Year 2024-25

Dr. Reddy's Laboratories Limited to Report Q4, 2025 Results on May 09, 2025

Dr. Reddy's Issues Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 Mg/100 mL, in the U.S., Due to Mislabeling of Infusion Bag

Senores Pharmaceuticals, Inc. agreed to acquire basket of 14 Abbreviated New Drug Applications from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Provides Lawsuit Updates

Dr. Reddy's Laboratories Limited to Report Q3, 2025 Results on Jan 23, 2025

Dr. Reddy's Laboratories Ltd. Launches Toripalimab in India

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Complaint Made Public in the United States District Court for the District of New Jersey

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Fiscal Year 2024

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

マネジメント基準チェック /34